Re: Minutes from the 2/24/16 DDI Information task force discussion (content sub group)

On Sat, Mar 26, 2016 at 11:45 PM, jrhorn <jrhorn@u.washington.edu> wrote:

> Tim
>
>
>
> Not sure why. Not sure what it does. This is difficult to load, but it
> looks like it is a DrugBank database. I would avoid using for any clinical
> purpose.
>
>
>
> What is it?
>
>
>
> John
>


Apologies for being to vague.  Why are people doing this DDI work when this
great resource is already available?
If ou are not familiar with RxNorm, a little bit of observation and reading
will explain what it is.



>
>
> *From:* Timothy Cook [mailto:tim@datainsights.tech]
> *Sent:* Saturday, March 26, 2016 3:30 PM
> *To:* Richard Boyce
> *Cc:* public-semweb-lifesci@w3.org; linikujp@gmail.com;
> brian.lebaron@va.gov; BHocum@genelex.com; CJVITALE@partners.org;
> Cui.Tao@uth.tmc.edu; malone@pharmacy.arizona.edu;
> daniela.oliveira@insight-centre.org; eric@squishymedia.com;
> draper.evan@mayo.edu; george.lilly@va.gov; gmcevoy@ashp.org;
> jschneider@pobox.com; harryh@pitt.edu; jeffnielson@gmail.com;
> sundaram.medimmune@gmail.com; jrhorn@u.washington.edu; jklimek@ncpdp.org;
> jp@rxdoc.me; jmbanda@stanford.edu; kak59@pitt.edu; kim.nolen@pfizer.com;
> laura.slaughter@gmail.com; lori.idemoto@gmail.com;
> peters@pharmacy.arizona.edu; maria.herrero@kcl.ac.uk;
> Breitenstein.Matthew@mayo.edu; MBrochhausen@uams.edu;
> matthias.samwald@meduniwien.ac.at; michel.dumontier@stanford.edu;
> Michael.Miller@systemsbiology.org; michael.liebman@ipqanalytics.com;
> mail@jackpo.org; nancy@worldvista.org; nick.tatonetti@columbia.edu;
> hassanzadeh@us.ibm.com; yongqunh@med.umich.edu; olivier@nlm.nih.gov;
> beyan@dbis.rwth-aachen.de; nytroe@idi.ntnu.no;
> ratnesh.sahay@insight-centre.org; Freimuth.Robert@mayo.edu;
> Sam.habiel@gmail.com; scott.nelson.rx@gmail.com; serkanayvaz@gmail.com;
> valerie@genelex.com; xjing2007@gmail.com
> *Subject:* Re: Minutes from the 2/24/16 DDI Information task force
> discussion (content sub group)
>
>
>
> Why?
>
>
>
> https://rxnav.nlm.nih.gov/InteractionAPIs.html#
> <https://rxnav.nlm.nih.gov/InteractionAPIs.html>
>
>
>
>
>
>
>
> On Sat, Mar 26, 2016 at 1:01 PM, Richard Boyce <rdb20@pitt.edu> wrote:
>
> (FYI for folks on the public-semweb-lifesci list who are not participating
> in the task force [1])
>
> Hello,
>
> Below I have pasted the minutes from the last meeting of the content
> sub-team for the DDI Minimum Information Model task force [1].  I apologize
> that I was forgot to record the meeting but I have tried to write detailed
> minutes. The full set of minutes for the task force are available [2].
>
> 1. https://sites.google.com/site/ddikrandir/home/ddi_info_model_taskforce
> 2. https://goo.gl/TKWfNN
>
> ------------
> Minutes for 2/24/2016 (Content subgroup)
>
>
>
> *In Attendance : Dan Malone, Evan Draper, John Horn, Oktie Hassanzadeh,
> Richard Boyce, Sam Habiel*
>
>
>
> Meeting recording: None taken (Rich forgot to start the recording, Sorry!)
>
>
>
> Meeting:
>
> ·         Brief discussion of progress on the *proposed task force
> activities:*
>
>
>
> 1.    *Clarify definitions *for the seven minimum information items
> recommended by prior AHRQ drug interaction conference series
>
> o    A sub-team has been working on creating definitions. Initial ideas
> have been developed and will be discussed over the next month:
> https://goo.gl/N0MxPd
>
> o    Some questions were raised by the sub-team that were discussed later
> during the meeting.
>
>
>
> 2.    *Propose additional attributes*
>
> o    Depends on Activity 1
>
>
>
> 3.    *Create deliverables* using an interesting and non-trivial set of
> potential drug-drug interactions:
>
> o    Depends on Activities 1 and 2
>
> 4.    *Create a foundation for further collaborative work* by
> disseminating results through an interest group note, a website, and an
> online discussion forum
>
> o    Ratnesh Sahay has created a project that will be used for advancing
> development of the interest group note:
> https://github.com/W3C-HCLS/w3c-ddi
>
>                                       i.        A very initial outline
> can be seen here: http://goo.gl/ZMU1Wm
>
>                                      ii.        All persons who have
> participated in the calls have been listed as contributors for now (in
> alphabetical order by first name). Please email Rich Boyce with spelling
> corrections and the affiliation you would like (or if you would like your
> name removed)
>
> o    Scott Nelson submitted a panel proposal on 3/10 to AMIA to discuss
> the topic of including seriousness as a minimum information item
>
>
>
> ·         Discussion of what DDI content to include in our deliverables.
>
> o    Sub-team members had made progress on suggesting interacting pairs
> based on known issues with DDI evidence and knowledge
>
> §  See https://goo.gl/rYpmjt
>
> o    Rich created a survey to increase the participation:
> https://pitt.co1.qualtrics.com/jfe/form/SV_0GPfzm7UbGDYV5X
>
> §  *Survey closes EOB Wednesday 3/30*
>
> o    It was decided that only one or two PDDIs will be selected for each
> category. The group agreed that, for each PDDI, a decision tree will be
> created that provides 1) information that can help contextualize the
> interaction depending on drug and patient factors, 2) management
> recommendations depending on the contextualizing factors in (1), and 3)
> evidence supporting or refuting each scientific claim made for (1)
>
> §  Such decision trees have already been created by John Horn and Phil
> Hansten for several interactions as part of Dan Malone’s AHRQ grant
> (R21HS023826).
>
> ·         These can be used for the project as long as we provide
> citation to the authors and grant.
>
> ·         These interactions might fit as representative for certain
> information categories. The group agreed that, for those cases, additional
> interactions will be chosen to provide heterogeneity
>
> ·         Discussion of stakeholders
>
> o    The question of who the stakeholders are for the min info model came
> up from the Standard sub-team. The content sub-team agreed that the
> stakeholders included primarily the following:
>
> §  Clinicians (doctors, nurses, pharmacists, and various practitioners)
> who must use PDDI information to make clinical decisions
>
> §  Persons who create systems that provide PDDI information to clinicians
> in various settings (e.g., database vendors, drug information editorial
> boards)
>
> §  Organizations that provide publicly available lists of drug-drug
> interactions (e.g., developers of RxNorm)
>
> o    Clarification of this in writing is planned
>
> ·         Discussion of use cases:
>
> o    Members of the standard sub-team had suggested using Medication
> Reconciliation as a target use case for showing the value of the info model
> (e.g., competency questions). Rich asked the content sub-team for comment
>
> §  It was agreed that med rec is an important use case but one that can
> probably be broken down into a number of smaller use cases depending on the
> phase of the medication therapy process in question (e.g., ordering,
> consulting, monitoring)
>
> o    Clarification of this in writing is planned and also a focused
> discussion at our “all team” meeting in May.
>
> ·         *Action Items*
>
> §  Rich will merge the final results of the survey on suggested PDDIs (
> https://pitt.co1.qualtrics.com/jfe/form/SV_0GPfzm7UbGDYV5X) into the
> google sheet (https://goo.gl/rYpmjt)
>
> §  He will then go through and highlight the PDDIs for which decision
> trees have been created as part of Dan Malone’s AHRQ grant
>
>    - The next meeting will finalize the list and future meetings will
>          finalize decision trees for the chosen interactions. In parallel, the
>          standard sub-team will work on representing the chosen interactions,
>          seeking feedback as they go.
>
>
>
> --
>
> Richard D Boyce, PhD
>
> Assistant Professor of Biomedical Informatics
>
> Faculty, Center for Pharmaceutical Policy and Prescribing
>
> Faculty, Geriatric Pharmaceutical Outcomes and Gero-Informatics Research and Training Program
>
> University of Pittsburgh
>
> rdb20@pitt.edu
>
> Office: 412-648-9219
>
> Twitter: @bhaapgh
>
>
>
>
>
> --
>
> Timothy W. Cook, President
>
> Data Insights, Inc.
>



-- 
Timothy W. Cook, President
Data Insights, Inc.